Value-added medicines specialist Hyloris Pharmaceuticals SA has via its partner AFT Pharmaceuticals struck an exclusive licensing agreement in China for its Maxigesic IV (paracetamol/ibuprofen) solution for infusion, bringing on board as a commercial partner a subsidiary of Chinese injectables specialist Xizang Weixinkang Pharmaceutical.
Hyloris Finds A Partner In China For Maxigesic IV Amid Business Disruptions
Intravenous Non-Opioid Pain Treatment Launched In More Than 30 Countries
Hyloris recognized that the suspension of its shares as part of a broader business fallout has “created uncertainty and temporarily impacted management and organizational focus,” as it got another commercial deal over the line for its Maxigesic IV (paracetamol/ibuprofen) solution for infusion.
More from Deals
More from Business
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.